P/E at 36.66 vs Industry's 37.21: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Slight Discount to Industry Average

The stock’s P/E ratio of 36.66 indicates it is trading at a modest discount of approximately 1.5% relative to the sector average of 37.21. This suggests that Sun Pharmaceutical Industries Ltd is valued in line with its peers, reflecting neither a significant premium nor a deep discount. Given the sector’s broad valuation band, this positioning implies that the market is pricing in fundamentals comparable to the industry norm. The slight discount could be interpreted as a cautious stance by investors, especially considering the stock’s recent performance volatility — previously rated Hold, what is Sun Pharma’s current rating?

Performance Across Timeframes: Divergent Momentum

Examining returns over various periods reveals a complex momentum profile. Over the past year, the stock has delivered a robust 23.70% gain, significantly outperforming the Sensex’s 4.87% loss. This outperformance extends to longer horizons as well, with three-year and five-year returns of 74.60% and 144.96% respectively, dwarfing the Sensex’s 16.62% and 31.80% gains over the same periods.

However, the short-term picture is less consistent. The stock’s one-month return stands at -2.71%, slightly underperforming the Sensex’s -2.36%. Yet, over three months, it has rebounded with an 8.13% gain, outperforming the Sensex’s 2.15%. Year-to-date, the stock has gained 12.54%, contrasting with the Sensex’s 10.52% decline. This pattern of short-term weakness followed by medium-term recovery — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — highlights the stock’s shifting momentum dynamics.

Moving Average Configuration: Bullish Across All Key Averages

Technically, Sun Pharmaceutical Industries Ltd is trading above all major moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day. This comprehensive positioning above short, medium, and long-term averages signals a strong technical foundation and suggests the stock is in a sustained uptrend. The absence of any recent breakdown below these averages further supports the view of technical resilience despite the recent two-day consecutive decline resulting in a 1.4% loss.

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen 34 stocks declare results recently, with 14 reporting positive outcomes, 15 flat, and 5 negative. This distribution indicates a broadly stable sector environment with a slight tilt towards positive results. Within this context, Sun Pharmaceutical Industries Ltd’s performance aligns with the sector’s mixed but generally steady trend. The stock’s market capitalisation of ₹4,63,180 crores places it firmly in the large-cap category, underscoring its significance within the sector.

Rating Reassessment: Previously Hold, Now Updated

MarketsMOJO had previously rated Sun Pharmaceutical Industries Ltd as Hold. The rating was reassessed on 25 Aug 2026, reflecting updated analysis of the company’s fundamentals, valuation, and technicals. The current Mojo Score stands at 74.0, indicating a positive momentum shift. This reassessment comes amid the stock’s strong relative performance over one year and its technical positioning above all key moving averages — should investors in Sun Pharma hold, buy more, or reconsider?

Comparative Performance: Outperforming Sensex Over Most Horizons

Over the last decade, Sun Pharmaceutical Industries Ltd has delivered a 147.46% return, slightly below the Sensex’s 167.25% gain. However, over five years, the stock’s 144.96% return far exceeds the Sensex’s 31.80%, and the three-year return of 74.60% also outpaces the Sensex’s 16.62%. This indicates that the stock has generated significant alpha in the medium term despite lagging slightly over the very long term.

Shorter-term returns further highlight the stock’s resilience. The one-week gain of 1.81% contrasts with the Sensex’s 1.58% loss, and the one-day gain of 0.26% outperforms the Sensex’s 0.90% decline. These data points reinforce the stock’s relative strength in recent trading sessions, even as it experienced a minor two-day losing streak with a 1.4% drop — is this a temporary setback or a sign of deeper weakness?

Market Capitalisation and Sector Positioning

With a market capitalisation of ₹4,63,180 crores, Sun Pharmaceutical Industries Ltd is a dominant player in the Pharmaceuticals & Biotechnology sector. Its size and liquidity make it a key stock within the large-cap universe, and its valuation close to the sector average suggests it is fairly priced relative to peers. The sector’s mixed result pattern, with nearly equal numbers of positive and flat outcomes, provides a backdrop of cautious optimism for the stock’s ongoing performance.

Conclusion: Data Reflects a Balanced Yet Positive Outlook

The data for Sun Pharmaceutical Industries Ltd paints a picture of a stock trading at a valuation closely aligned with its sector, supported by strong medium- and long-term performance and a robust technical setup. The recent rating reassessment from Hold to a more positive stance reflects these factors. While short-term returns have shown some volatility, the overall momentum remains constructive. The sector’s mixed results and the stock’s large-cap status further contextualise its performance within a competitive industry landscape — what does the current rating imply for investors looking at Sun Pharma now?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →